TSE:APS

Aptose Biosciences Competitors

C$6.61
+0.11 (+1.69 %)
(As of 04/9/2021 04:00 PM ET)
Add
Compare
Today's Range
C$6.40
Now: C$6.61
C$6.71
50-Day Range
C$4.45
MA: C$5.75
C$7.85
52-Week Range
C$4.32
Now: C$6.61
C$12.62
Volume24,779 shs
Average Volume64,934 shs
Market CapitalizationC$587.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Aptose Biosciences (TSE:APS) Vs. TRIL, CXR, BU, TH, BLU, and NRI

Should you be buying APS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Aptose Biosciences, including Trillium Therapeutics (TRIL), Concordia International (CXR), Burcon NutraScience (BU), Theratechnologies (TH), BELLUS Health (BLU), and Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI).

Trillium Therapeutics (TSE:TRIL) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Trillium Therapeutics and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics0000N/A
Aptose Biosciences00203.00

Trillium Therapeutics currently has a consensus price target of C$25.00, indicating a potential upside of 91.42%. Aptose Biosciences has a consensus price target of C$12.00, indicating a potential upside of 81.54%. Given Trillium Therapeutics' higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than Aptose Biosciences.

Earnings and Valuation

This table compares Trillium Therapeutics and Aptose Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium TherapeuticsC$148,000.009,091.97C$-90,772,073.00C($0.88)-14.82
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79

Aptose Biosciences has lower revenue, but higher earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trillium Therapeutics and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/AN/AN/A
Aptose BiosciencesN/AN/AN/A

Summary

Aptose Biosciences beats Trillium Therapeutics on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Concordia International (TSE:CXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Profitability

This table compares Aptose Biosciences and Concordia International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Concordia InternationalN/AN/AN/A

Valuation & Earnings

This table compares Aptose Biosciences and Concordia International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79
Concordia InternationalC$569.62 million2.15C$17.20 billionC$351.680.07

Concordia International has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aptose Biosciences and Concordia International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Concordia International0000N/A

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Given Aptose Biosciences' higher possible upside, equities research analysts clearly believe Aptose Biosciences is more favorable than Concordia International.

Summary

Concordia International beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Earnings and Valuation

This table compares Aptose Biosciences and Burcon NutraScience's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00

Burcon NutraScience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and Burcon NutraScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Burcon NutraScience00103.00

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Burcon NutraScience has a consensus target price of C$5.00, indicating a potential downside of 7.75%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Burcon NutraScience.

Summary

Burcon NutraScience beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
TheratechnologiesN/AN/AN/A

Earnings and Valuation

This table compares Aptose Biosciences and Theratechnologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79
TheratechnologiesC$66.05 million6.78C$-27,589,254.00C($0.29)-16.22

Aptose Biosciences has higher earnings, but lower revenue than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and Theratechnologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Theratechnologies02002.00

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Theratechnologies has a consensus target price of C$3.75, indicating a potential downside of 21.38%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Theratechnologies.

Summary

Aptose Biosciences beats Theratechnologies on 4 of the 6 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
BELLUS HealthN/AN/AN/A

Earnings and Valuation

This table compares Aptose Biosciences and BELLUS Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79
BELLUS HealthC$15,000.0028,462.44C$-42,145,306.00C($0.54)-10.13

Aptose Biosciences has higher earnings, but lower revenue than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and BELLUS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
BELLUS Health01202.67

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than BELLUS Health.

Summary

Aptose Biosciences beats BELLUS Health on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Earnings and Valuation

This table compares Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million0.14C$-6,980,844.00C($0.61)-1.48

Aptose Biosciences has higher earnings, but lower revenue than Nuvo Pharmaceuticals Inc. (NRI.TO). Aptose Biosciences is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals Inc. (NRI.TO), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Summary

Nuvo Pharmaceuticals Inc. (NRI.TO) beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.


Aptose Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRIL
Trillium Therapeutics
0.9$13.06+7.6%C$1.32 billionC$148,000.00-14.82
Concordia International logo
CXR
Concordia International
0.7$25.04+1.6%C$1.22 billionC$569.62 million0.07High Trading Volume
BU
Burcon NutraScience
1.2$5.42+0.9%C$580.49 millionC$12,045.005,420.00
Theratechnologies logo
TH
Theratechnologies
0.7$4.77+0.8%C$447.62 millionC$66.05 million-16.22Upcoming Earnings
BLU
BELLUS Health
0.5$5.45+1.5%C$426.94 millionC$15,000.00-10.13
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
1.0$0.91+4.4%C$409.34 millionC$76.09 million-1.48Gap Up
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5$13.60+0.2%C$315.66 millionC$39.91 million-0.22
NEPT
Neptune Wellness Solutions
1.2$1.77+4.0%C$292.92 millionC$52.78 million-1.31
MDNA
Medicenna Therapeutics
0.5$5.08+0.8%C$268.74 millionN/A-16.44
ONC
Oncolytics Biotech
1.0$4.99+16.2%C$259.90 millionN/A-8.91
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.62+0.6%C$245.11 millionC$3,000.00-6.26
ATE
Antibe Therapeutics
1.3$4.88+1.0%C$222.07 millionC$9.33 million-6.20
FRX
Fennec Pharmaceuticals
0.5$7.82+6.5%C$203.34 millionC$170,000.00-10.24Gap Up
RVX
Resverlogix
0.7$0.86+0.0%C$202.07 millionN/A78.18Upcoming Earnings
HBP
Helix BioPharma
0.5$0.92+1.1%C$129.84 millionN/A-16.73
IPA
ImmunoPrecise Antibodies
0.4$15.41+4.9%C$123.03 millionC$17.18 million-72.01Gap Up
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.68+1.5%C$88.79 millionC$81,000.0020.00Gap Down
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
PMN
ProMIS Neurosciences
0.5$0.22+0.0%C$67.31 millionC$1,787.00-11.00
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.55+3.6%C$60.20 millionC$11.64 million-10.78
SBM
Sirona Biochem
0.5$0.38+1.3%C$58.80 millionC$123,870.00-29.23
COV
Covalon Technologies
0.6$1.41+0.7%C$37.44 millionC$23.84 million-5.92
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.29+1.7%C$34.02 millionC$13.02 million-0.42
IGX
IntelGenx Technologies
0.9$0.57+3.5%C$30.87 millionC$1.54 million-8.77
QPT
Quest PharmaTech
0.8$0.11+9.1%C$21.76 millionC$38,871.000.17High Trading Volume
CZO
Ceapro
0.7$0.72+4.2%C$21.65 millionC$16.14 million21.82
CTX
Crescita Therapeutics
0.6$0.86+2.3%C$17.76 millionC$15.64 million430.00Gap Up
KNE
Kane Biotech
0.4$0.17+0.0%C$14.12 millionC$1.34 million-4.86
GSD
Devonian Health Group
0.5$0.27+3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09+5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60+5.0%C$10.80 millionC$12.71 million-1.03Gap Down
BTI
Bioasis Technologies
0.7$0.39+3.8%C$10.16 millionC$4.12 million35.45
HEM
Hemostemix
0.6$0.49+1.0%C$9.07 millionN/A-2.92Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75News Coverage
IBT
IBEX Technologies
0.7$0.36+1.4%C$6.94 millionC$5.60 million6.57Gap Down
IOT
Innovotech
0.8$0.15+3.3%C$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$6.40+15.3%C$4.48 millionN/A-2.07High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5$2.95+2.7%C$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7$42.77+1.3%C$0.00C$267.59 million47.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.